U.S. markets close in 2 hours 7 minutes

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4700-0.0050 (-0.14%)
As of 1:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close3.4750
Bid3.4700 x 1200
Ask3.4800 x 1800
Day's Range3.4250 - 3.5600
52 Week Range1.4500 - 5.5000
Avg. Volume4,100,066
Market Cap590.32M
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)-0.1760
Earnings DateMar 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is an EUA for Rigel’s COVID-19 Treatment in the Cards? Analyst Weighs In

    Is an EUA for Rigel’s COVID-19 Treatment in the Cards? Analyst Weighs In

    Several coronavirus stocks were on the move this week in reaction to the CDC (Centers for Disease Control and Prevention) and the FDA both suggesting a halt to the use of Johnson & Johnson's COVID-19 vaccine. The recommendation followed the news that some individuals developed serious blood clots just days after receiving the one-shot vaccine. Meanwhile, a less lauded coronavirus stock also posted some impressive gains, but its surge had less to do with a rival’s failure and based on its own achievements. Shares of Rigel Pharmaceuticals (RIGL) climbed this week after the company released positive topline data from the phase 2 clinical study of Tavalisse (fostamatinib) for the treatment of hospitalized COVID-19 patients. The trial is in collaboration with the National Institutes of Health (NIH) and Inova Health System and included 59 hospitalized COVID-19 patients, who for twice a day over a 14-day period, were given either Tavalisse plus standard of care or a placebo plus standard of care. There were several positives in the trial. The treatment met its primary endpoint of safety, and cut the occurrence of Serious Adverse Events (SAEs) by half. There were no deaths among the patients who took Tavalisse compared to three in the placebo cohort. Next up, Rigel will discuss with the FDA the possibility of an EUA (emergency use authorization) filing for the treatment. H.C. Wainwright’s Joseph Pantginis says there are two main factors to consider now. On the one hand, while the trial has shown “dramatic effects,” the study was relatively small. However, standing in Tavalisse’s stead is the fact it is already approved as a treatment for adult chronic immune thrombocytopenia, with a long-term safety database numbering roughly 4,800. This means it is “not a new molecular entity seeking first approval.” “To this end,” the 5-star analyst notes, “We believe an early case is being made for the FDA to approve an EUA. The risk to this case at this point, in our view, is that the agency requires the readout of Rigel's Phase 3, though it is in earlier stage patients with a progression endpoint. Overall, we are impressed with the data and believe that Tavalisse should make its way to COVID patients.” Accordingly, Pantginis rates RIGL shares a Buy along with an $11 price target. Investors could be sitting on gains of 207%, should the target be met over the next 12 months. (To watch Pantginis’ track record, click here) There’s widespread agreement on Wall Street regarding Rigel’s trajectory. Based on Buys only – 4, in total – the stock has a Strong Buy consensus rating. The average price target comes in at $8.75, suggesting upside of 144% within the 12-month time frame. (See RIGL stock analysis on TipRanks) To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Company News for Apr 14, 2021

    Company News for Apr 14, 2021

    Companies in the news are: MFNC, NVCR, RIGL, VTVT